HIPK1 and cardiac hypertrophy: We further observed that adeno‐associated virus (AAV)9‐mediated gene therapy that reduced HIPK1 via shRNA approach protected against pathological cardiac hypertrophy and heart failure, and delineated that CREB inhibition was essential to mediate the beneficial effect of reducing HIPK1 in preventing pathological cardiac hypertrophy.